SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 155 filers reported holding SAGE THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 1.15 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $4,118,000 | +47.3% | 25,000 | -44.3% | 1.93% | +48.4% |
| Q3 2017 | $2,796,000 | -48.3% | 44,872 | -33.9% | 1.30% | -65.8% |
| Q2 2017 | $5,405,000 | -23.3% | 67,872 | -31.5% | 3.80% | +5.2% |
| Q1 2017 | $7,045,000 | +20.9% | 99,123 | -13.1% | 3.61% | -13.5% |
| Q4 2016 | $5,827,000 | -4.6% | 114,123 | -14.0% | 4.17% | -5.1% |
| Q3 2016 | $6,110,000 | +29.2% | 132,674 | -15.5% | 4.40% | +8.1% |
| Q2 2016 | $4,729,000 | +3.5% | 156,958 | +10.1% | 4.07% | -1.7% |
| Q1 2016 | $4,571,000 | +353.5% | 142,570 | +498.3% | 4.14% | +373.3% |
| Q3 2015 | $1,008,000 | -54.2% | 23,829 | -45.6% | 0.87% | -41.5% |
| Q1 2015 | $2,199,000 | +69.8% | 43,770 | +23.7% | 1.49% | +137.0% |
| Q4 2014 | $1,295,000 | – | 35,370 | – | 0.63% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 312,000 | $29,886,000 | 5.11% |
| DAFNA Capital Management LLC | 104,306 | $9,991,000 | 4.97% |
| Palo Alto Investors LP | 850,977 | $81,515,000 | 4.34% |
| BB BIOTECH AG | 1,375,229 | $131,733,000 | 4.22% |
| Eventide Asset Management | 936,000 | $89,659,000 | 3.97% |
| TRV GP II, LLC | 37,362 | $3,579,000 | 3.56% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 146,179 | $14,002,000 | 2.11% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 111,908 | $10,720,000 | 2.06% |
| OAK RIDGE INVESTMENTS LLC | 231,483 | $22,174,000 | 1.60% |
| Rhenman & Partners Asset Management AB | 137,339 | $13,156,000 | 1.50% |